^
Association details:
| Biomarker: | FOLH1 overexpression |
|---|---|
| Cancer: | Clear Cell Renal Cell Carcinoma |
| Drug: | sunitinib (c-KIT inhibitor, VEGFR inhibitor, PDGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PD59-02 PROSTATE SPECIFIC MEMBRANE ANTIGEN EXPRESSION IS ASSOCIATED WITH ANGIOGENESIS AND TYROSINE KINASE INHIBITOR RESPONSE IN CLEAR CELL RENAL CELL CARCINOMA
Published date:
04/09/2022
Excerpt:
We evaluated the relation between FOLH1 expression and angiogenesis, as well as clinical outcomes, in two prior large trials of IO and/or TKI in m-ccRCC....In COMPARZ, patients with high FOLH1 expression (> median expression value) had improved OS and PFS compared to those with low FOLH1 expression in the sunitinib, but not pazopanib, arm (Log-rank p = 0.014 and 0.024 vs 0.44 and 0.29, respectively)….In IMmotion 150, patients with complete/partial response to sunitinib had significantly higher expression of FOLH1 than non-responders (mean score 30 vs 24, Wilcoxon p = 0.049)…
DOI:
https://doi.org/10.1097/JU.0000000000002644.02
